Carcinoma in situ of other and unspecified sites

DOID MESH PheWeb

CD2_INSITU_OTHER_NOS

No definition available.

Endpoint definition

↥

FinnGen phenotype data

321302 individuals

Apply sex-specific rule None

321302

Check conditions None

321302

Filter registries

Hospital Discharge: ICD-10 D09

Cause of death: ICD-10 D09

Check pre-conditions, main-only, mode, ICD version

Look only at ICD versions H.D: 10 ; C.O.D: 10

Check minimum number of events None

Include endpoints

CD2_INSITU_BLADDER

CD2_INSITU_URINARY_NOS

CD2_INSITU_EYE

CD2_INSITU_THYROICD2_ENDOCRINE

CD2_INSITU_NOS

CD2_INSITU_OTHER_NOS

Extra metadata

Level in the ICD hierarchy 2

First used in FinnGen datafreeze DF2

Parent code in ICD-10 D00-D09

Name in latin Carcinoma in situ locis aliis sive non specificatis

Similar endpoints

↥

List of similar endpoints to Carcinoma in situ of other and unspecified sites based on the number of shared cases.

Broader endpoints:

Narrower endpoints:

Show all endpoint correlations

Summary Statistics

↥

Key figures

All

Female

Male

Number of individuals

Unadjusted prevalence (%)

0.03

0.02

0.04

Mean age at first event (years)

64.74

56.70

68.69

?

Follow-up

Amount of time to look for the endpoint since entering the study. This is either either 1, 5, 15 years or the full study time from 1998 to 2019.

Absolute risk

Estimates the probability of dying from the current endpoint. Check the Documentation page for Mortality: absolute risk to get more details.

Hazard Ratio (HR) and 95% Confidence Interval (CI)

Measures how much the risk of dying increases (HR > 1) or decreases (HR < 1).

Number of individuals (N)

Number of individuals having the current endpoint and died during the follow-up time.
Mortality

Follow-up	Absolute risk	HR [95% CI]	p	N
1998–2019	-	-	-	-
15 years	-	-	-	-
5 years	-	-	-	-
1 year	-	-	-	-

Age distribution of first events

Year distribution of first events

Cumulative Incidence

Correlations

↥

Index endpoint: CD2_INSITU_OTHER_NOS – Carcinoma in situ of other and unspecified sites
GWS hits:

Survival analyses between endpoints

↥

Plot

before Carcinoma in situ of other and unspecified sites
after Carcinoma in situ of other and unspecified sites

Loading survival analyses plot

Table

Loading survival analyses table

Drugs most likely to be purchased after Carcinoma in situ of other and unspecified sites

↥